

antipyrene in African patients with Hodgkin's lymphoma.

Juma, F.D

Abstract:

The pharmacokinetics of antipyrene were studied in 12 healthy volunteers and 10 patients of Kenya African origin with Hodgkin's lymphoma. The half-life of antipyrene was 12.2 ± 1.3 h (mean \pm s.d.), while the apparent volume of distribution (V) was 0.67 ± 0.11 l kg⁻¹ (mean \pm s.d.) and the total body clearance was 40.7 ± 3.2 ml kg⁻¹ h⁻¹ (mean \pm s.d.) in the healthy volunteers. The antipyrene half-life in the patients with advanced Hodgkin's lymphoma was 17.1 ± 2.7 h (mean \pm s.d.). The apparent volume of distribution was 0.72 ± 0.14 l kg⁻¹ (mean \pm s.d.) which was larger than in healthy volunteers (P less than 0.05). The total body clearance was 30.3 ± 9.4 ml kg⁻¹ h⁻¹ (mean \pm s.d.) and this was reduced compared with that in healthy volunteers (P less than 0.02). After cytotoxic therapy the half-life in the patients with advanced Hodgkin's lymphoma was significantly decreased to 8.3 ± 1.3 h (mean \pm s.d.) (P less than 0.07), and the apparent volume of distribution was reduced to 0.65 ± 0.07 l kg⁻¹ (mean \pm s.d.) (P less than 0.05) while the total body clearance increased to 52.8 ± 5.5 ml kg⁻¹ h⁻¹ (mean \pm s.d.) (P less than 0.01).